Revenue Recognition - Performance Obligations - Additional Information (Details) $ in Millions		1 Months Ended			12 Months Ended
	Jul. 27, 2020 Obligation	Oct. 31, 2023 USD ($)	Aug. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Dec. 31, 2023	Dec. 31, 2022 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended					75 days
MAT2A Supply
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue recognized						$ 2.4
GSK
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended					75 days
Revenue recognized						$ 17.4
GSK Collaboration Agreement
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Number of performance obligations | Obligation	6
Pol Theta Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Milestone payment received clinical evaluation			$ 7.0
Milestone payment received for achievement of earlier preclinical development milestone			3.0	$ 3.0
Additional milestone payment potentially received clinical evaluation			$ 10.0
Reimbursement period of costs incurred for quarter ended					90 days
WRN Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Milestone payment received clinical evaluation		$ 3.0
Milestone payment received for achievement of earlier preclinical development milestone		$ 3.0
Reimbursement period of costs incurred for quarter ended					75 days
Determination period of costs incurred					75 days